277 related articles for article (PubMed ID: 16465432)
1. Osteosarcoma: current status of immunotherapy and future trends (Review).
Mori K; Rédini F; Gouin F; Cherrier B; Heymann D
Oncol Rep; 2006 Mar; 15(3):693-700. PubMed ID: 16465432
[TBL] [Abstract][Full Text] [Related]
2. Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma.
Weibo P; Zhaoming Y
Med Hypotheses; 2012 May; 78(5):616-8. PubMed ID: 22330890
[TBL] [Abstract][Full Text] [Related]
3. Is there a role for immunotherapy in osteosarcoma?
Loeb DM
Cancer Treat Res; 2009; 152():447-57. PubMed ID: 20213407
[TBL] [Abstract][Full Text] [Related]
4. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
5. Osteosarcoma. Results of treatment employing adjuvant immunotherapy.
Eilber FR; Townsend C; Morton DL
Clin Orthop Relat Res; 1975 Sep; (111):94-100. PubMed ID: 1057467
[TBL] [Abstract][Full Text] [Related]
6. Midkine as a novel target for antibody therapy in osteosarcoma.
Maehara H; Kaname T; Yanagi K; Hanzawa H; Owan I; Kinjou T; Kadomatsu K; Ikematsu S; Iwamasa T; Kanaya F; Naritomi K
Biochem Biophys Res Commun; 2007 Jul; 358(3):757-62. PubMed ID: 17506984
[TBL] [Abstract][Full Text] [Related]
7. Glycosaminoglycans as potential regulators of osteoprotegerin therapeutic activity in osteosarcoma.
Lamoureux F; Picarda G; Garrigue-Antar L; Baud'huin M; Trichet V; Vidal A; Miot-Noirault E; Pitard B; Heymann D; Rédini F
Cancer Res; 2009 Jan; 69(2):526-36. PubMed ID: 19147566
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption.
Lamoureux F; Richard P; Wittrant Y; Battaglia S; Pilet P; Trichet V; Blanchard F; Gouin F; Pitard B; Heymann D; Redini F
Cancer Res; 2007 Aug; 67(15):7308-18. PubMed ID: 17671200
[TBL] [Abstract][Full Text] [Related]
9. Strategies to explore new approaches in the investigation and treatment of osteosarcoma.
Kim SY; Helman LJ
Cancer Treat Res; 2009; 152():517-28. PubMed ID: 20213413
[TBL] [Abstract][Full Text] [Related]
10. Receptor activator of nuclear factor-kappaB ligand (RANKL) directly modulates the gene expression profile of RANK-positive Saos-2 human osteosarcoma cells.
Mori K; Berreur M; Blanchard F; Chevalier C; Guisle-Marsollier I; Masson M; Rédini F; Heymann D
Oncol Rep; 2007 Dec; 18(6):1365-71. PubMed ID: 17982618
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of sarcomas.
Leventhal BG
Natl Cancer Inst Monogr; 1981 Apr; (56):183-7. PubMed ID: 6170891
[TBL] [Abstract][Full Text] [Related]
12. Primary bone osteosarcoma in the pediatric age: state of the art.
Longhi A; Errani C; De Paolis M; Mercuri M; Bacci G
Cancer Treat Rev; 2006 Oct; 32(6):423-36. PubMed ID: 16860938
[TBL] [Abstract][Full Text] [Related]
13. [Osteosarcoma: current views on pathology and new therapeutic perspectives. II: Criteria of prognosis and treatment (author's transl)].
Zilioli E; Ottaviani C
Chir Ital; 1978 Dec; 30(6):975-91. PubMed ID: 380833
[TBL] [Abstract][Full Text] [Related]
14. Gene therapy for osteosarcoma: steps towards clinical studies.
Dass CR; Choong PF
J Pharm Pharmacol; 2008 Apr; 60(4):405-13. PubMed ID: 18380911
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy for osteosarcoma: Where do we go from here?
Wedekind MF; Wagner LM; Cripe TP
Pediatr Blood Cancer; 2018 Sep; 65(9):e27227. PubMed ID: 29923370
[TBL] [Abstract][Full Text] [Related]
16. Novel immunotherapeutic approaches to glioma.
Yamanaka R
Curr Opin Mol Ther; 2006 Feb; 8(1):46-51. PubMed ID: 16506525
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma.
Théoleyre S; Mori K; Cherrier B; Passuti N; Gouin F; Rédini F; Heymann D
BMC Cancer; 2005 Sep; 5():123. PubMed ID: 16188028
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors for the local recurrence of osteosarcoma in extremities treated with combined therapy].
Zhang Q; Niu XH; Cai YB; Hao L; Ding Y
Zhonghua Wai Ke Za Zhi; 2007 Aug; 45(16):1114-7. PubMed ID: 18005614
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies.
Lamoureux F; Trichet V; Chipoy C; Blanchard F; Gouin F; Redini F
Expert Rev Anticancer Ther; 2007 Feb; 7(2):169-81. PubMed ID: 17288528
[TBL] [Abstract][Full Text] [Related]
20. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
